<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111187</url>
  </required_header>
  <id_info>
    <org_study_id>J1402</org_study_id>
    <secondary_id>NA_00091602</secondary_id>
    <nct_id>NCT02111187</nct_id>
  </id_info>
  <brief_title>A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer</brief_title>
  <acronym>LDE225</acronym>
  <official_title>A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed as a randomized two-arm (LDE225 vs. observation groups) open-label
      prospective clinical trial in men with localized high-risk prostate cancer undergoing radical
      prostatectomy.

      The investigators propose to determine the effects of LDE225 on neoplastic prostate tissue
      from men at high risk of systemic disease progression, by comparing pre-surgical core-biopsy
      specimens to tumor tissue harvested at the time of prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-risk patients will be identified based on their core-needle biopsy features, PSA levels,
      and clinical stage. After obtaining baseline laboratory and clinical values (including an
      ECG, PSA, hematologic, and renal and hepatic panels), men will receive oral LDE225 800 mg/day
      or observation daily for 4 weeks (±3 days) prior to prostatectomy. Patients will have a
      clinical visit and an ECG and laboratory testing will be performed at 2 weeks and then again
      at 4 weeks, including a 4-week pre-prostatectomy measurement of PSA and a blood sample to
      determine plasma LDE225 levels. Men will undergo radical prostatectomy (with bilateral pelvic
      lymphadenectomy as appropriate), at which point two 250-mg biopsies of prostate tissue will
      be obtained, frozen and stored for analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">January 18, 2017</completion_date>
  <primary_completion_date type="Actual">January 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation)</measure>
    <time_frame>Up to 3 Years</time_frame>
    <description>This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of LDE225 on PSA Recurrence Following Prostatectomy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events in Each Group (LDE225 and Observation)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>LDE225 (Arm1)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Arm (Arm2)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <description>Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy</description>
    <arm_group_label>LDE225 (Arm1)</arm_group_label>
    <other_name>Sonidegib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent prior to any screening procedures.

          2. Age 18 years or older.

          3. Histologically-documented prostatic adenocarcinoma in ≥2 cores

          4. ECOG performance status ≤2

          5. Localized prostate cancer with at least one of the following NCCN high-risk features:

               -  Gleason sum ≥8

               -  PSA &gt;20 ng/mL

               -  Clinical stage ≥T3

          6. Must be a candidate for radical prostatectomy

          7. No evidence of known metastatic disease (M0 or Mx allowed)

          8. Adequate bone marrow, liver and renal function as specified below:

               -  Absolute neutrophil count (ANC) ≥ 1500/µL

               -  Hemoglobin (Hgb) ≥ 9.0 g/dL

               -  Platelets ≥100,000/µL

               -  Serum total bilirubin ≤ 1.5 x ULN (upper limit of normal)

               -  AST and ALT ≤ 2.5 x ULN

               -  Plasma creatine phosphokinase (CK) &lt; 1.5 x ULN, if known

               -  Serum creatinine ≤ 1.5 x ULN [or 24-hour creatinine clearance ≥ 50ml/min]

          9. Patient is able to swallow and retain oral medications

        Exclusion Criteria:

          1. Patients who have had major surgery within 4 weeks of enrollment.

          2. Patients with concurrent uncontrolled medical conditions that may interfere with their
             participation in the study.

          3. Patients unable to take oral drugs (e.g. lack of physical integrity of the upper GI
             tract or known malabsorption syndromes).

          4. Patients who have previously been treated with LDE225 or other Hh pathway inhibitors

          5. Patients who have neuromuscular or muscular disorders (e.g. inflammatory myopathies,
             muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are
             on concomitant treatment with drugs that are known to cause rhabdomyolysis (such as
             statins and fibrates), and that cannot be discontinued at least 2 weeks prior to
             starting LDE225. If it is essential that the patient stays on a statin for
             hyperlipidemia, only pravastatin may be used with extra caution. Patients should not
             plan to embark on a new strenuous exercise regimen after initiation of study
             treatment. (NB: Muscular activities, such as strenuous exercise, that can result in
             significant increases in plasma CK levels should be avoided whilst on LDE225
             treatment).

          6. Patients who have taken part in an experimental drug study within 4 weeks or 5
             half-lives (whichever is longer) of initiating treatment with LDE225.

          7. Patients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted
             therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225.

          8. Patients taking moderate/strong inhibitors or inducers of CYP3A4/5 or drugs
             metabolized by CYP2B6 or CYP2C9 that have narrow therapeutic index, and that cannot be
             discontinued before starting treatment with LDE225. Medications that are strong
             CYP3A4/5 inhibitors should be discontinued for at least 7 days and strong CYP3A/5
             inducers for at least 2 weeks prior to starting treatment with LDE225.

          9. No concurrent use of statins (except for pravastatin, if absolutely necessary)

         10. No concurrent warfarin or Coumadin-derivatives

         11. Impaired cardiac function or significant heart disease, including any one of the
             following:

               -  Angina pectoris within 3 months

               -  Acute myocardial infarction within 3 months

               -  QTc &gt;450 msec on the screening ECG

               -  A past medical history of clinically significant ECG abnormalities or a family
                  history of prolonged QT-interval syndrome

               -  Other clinically significant heart disease (e.g. heart failure,
                  uncontrolled/labile hypertension, or history of poor compliance with an
                  antihypertensive regimen)

         12. Patients who are not willing to apply highly effective contraception during the study
             and through the duration of LDE225 treatment.

               -  Male patients must use highly effective (double barrier) methods of contraception
                  (e.g., spermicidal gel plus condom) for the entire duration of the study, and
                  continuing using contraception and refrain from fathering a child for 6 months
                  following the last dose of the study drug. A condom is also required to be used
                  by vasectomized men as well as during intercourse with a male partner in order to
                  prevent delivery of the study treatment via seminal fluid. Sexually active males
                  must be willing to use a condom during intercourse while taking the study drug
                  and for 6 months after stopping investigational medications and agree not to
                  father a child during this period.

         13. Patients unwilling or unable to comply with the research protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel Antonarakis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <results_first_submitted>October 5, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2019</results_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LDE225</keyword>
  <keyword>High risk localized prostate cancer</keyword>
  <keyword>Pre-surgical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02111187/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LDE225 (Arm1)</title>
          <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
        </group>
        <group group_id="P2">
          <title>Observation Arm (Arm2)</title>
          <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LDE225 (Arm1)</title>
          <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
        </group>
        <group group_id="B2">
          <title>Observation Arm (Arm2)</title>
          <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation)</title>
        <description>This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.</description>
        <time_frame>Up to 3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LDE225 (Arm1)</title>
            <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
          </group>
          <group group_id="O2">
            <title>Observation Arm (Arm2)</title>
            <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tissue Gli1 Expression Levels Using qRT-PCR Analysis in Each Group (LDE225 and Observation)</title>
          <description>This was defined as the number of patients who achieved at least a two-fold reduction in GLI1 expression in post-treatment vs. pre-treatment tumor tissues.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225</title>
        <description>To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LDE225 (Arm1)</title>
            <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
          </group>
          <group group_id="O2">
            <title>Observation Arm (Arm2)</title>
            <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Pathological Effect of Presurgical Treatment With LDE225</title>
          <description>To determine whether presurgical treatment with LDE225 can exert a pathological effect on high-risk tumors (i.e. increase apoptosis, decrease proliferation).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Pathologic Gleason Sum 7</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pathologic Gleason Sum 9</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pathologic Gleason Sum 10</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of LDE225 on PSA Recurrence Following Prostatectomy</title>
        <description>To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LDE225 (Arm1)</title>
            <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
          </group>
          <group group_id="O2">
            <title>Observation Arm (Arm2)</title>
            <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of LDE225 on PSA Recurrence Following Prostatectomy</title>
          <description>To evaluate whether presurgical treatment with LDE225 diminishes the risk of PSA recurrence following prostatectomy.</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="3.2" upper_limit="29.7"/>
                    <measurement group_id="O2" value="7.4" lower_limit="2.4" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events in Each Group (LDE225 and Observation)</title>
        <description>Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LDE225 (Arm1)</title>
            <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
          </group>
          <group group_id="O2">
            <title>Observation Arm (Arm2)</title>
            <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events in Each Group (LDE225 and Observation)</title>
          <description>Safety and tolerability, including any drug-related toxicities of Sonidegib, were reported via CTCAE version 4.0.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>LDE225 (Arm1)</title>
          <description>Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
LDE225</description>
        </group>
        <group group_id="E2">
          <title>Observation Arm (Arm2)</title>
          <description>Observation Arm (Arm2) will receive no treatment prior to prostatectomy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>AST/ALT elevated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased CK level</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emmanuel Antonarakis</name_or_title>
      <organization>Associate professor of oncology and urology</organization>
      <phone>443-287-0553</phone>
      <email>eantona1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

